This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4SC-203

4SC AG

Drug Names(s): 4SC-203

Description: 4SC-203 is a novel, small molecule, multi-targetkinase inhibitor which has a unique selectivityprofile against FLT3, FLT3 mutants and VEGF-receptors. FLT3 is involved in the growth and maturation of normal blood cells, while VEGF receptor tyrosine kinases are involved in angiogenesis.

4SC-203 News

Pink Sheet Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine

Scrip Pipeline Watch: Phase II Starts In Hearing Loss, Type 1 Diabetes

Pink Sheet Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel

Scrip Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug